Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 1, 2006, Pages 45-50

  Bragantini, Emma ^a   Barbi, Stefano ^a   Beghelli, Stefania ^a   Moore, Patrick S ^a   De Manzoni, Giovanni ^a   Roviello, Franco ^b   Tomezzoli, Anna ^c   Vindigni, Carla ^b   Baffa, Raffaele ^d   Scarpa, Aldo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c BORGO TRENTO HOSPITAL   (Italy)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer; Fhit; Immunohistochemistry; Prognosis; Stomach

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STOMACH ADENOCARCINOMA;

ACID ANHYDRIDE HYDROLASES; AGED; ANALYSIS OF VARIANCE; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; LYMPHATIC METASTASIS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 28244470074     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-005-0045-9     Document Type: Article

References (29)

1. Baffa R, Veronese ML, Santoro R et al (1998) Loss of FHIT expression in gastric carcinoma. Cancer Res 58:4708-4714
2. Barnes LD, Garrison PN, Siprashvili Z et al (1996) Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5″'-P1,P3-triphosphate hydrolase. Biochemistry 35:11529-11535
3. Capuzzi D, Santoro E, Hauck WW et al (2000) Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 88:24-34
4. Chen YJ, Chen PH, Lee MD et al (1997) Aberrant FHIT transcripts in cancerous and corresponding non-cancerous lesions of the digestive tract. Int J Cancer 72:955-958
5. Croce CM, Sozzi G, Huebner K (1999) Role of FHIT in human cancer. J Clin Oncol 17:1618-1624
6. Gemma A, Hagiwara K, Ke Y et al (1997) FHIT mutations in human primary gastric cancer. Cancer Res 57:1435-1437
7. Hermanek P, Sobin L (1992) TNM classification of malignant tumours, UICC, 2nd revision. Springer, Berlin Heidelberg New York
8. Huiping C, Kristjansdottir S, Bergthorsson JT et al (2002) High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer 38:728-735
9. Ishii H, Dumon KR, Vecchione A et al (2001) Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 61:1578-1584
10. Ishii H, Zanesi N, Vecchione A et al (2003) Regression of upper gastric cancer in mice by FHIT gene delivery. Faseb J 17:1768-1770
11. Kawaguchi K, Yashima K, Koda M et al (2004) Fhit expression in human gastric adenomas and intramucosal carcinomas: correlation with Mlh1 expression and gastric phenotype. Br J Cancer 90:672-677
12. Kitamura A, Yashima K, Okamoto E et al (2001) Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology 61:205-211
13. Lauren P (1965) The two histological main types of gastric carrcinoma: diffuse and so called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31-49
14. Lee HS, Lee HK, Kim HS et al (2003) Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200:39-46
15. Lee SH, Kim CJ, Park HK et al (2001) Characterization of aberrant FHIT transcripts in gastric adenocarcinomas. Exp Mol Med 33:124-130
16. Lee SH, Kim HY, Kim TJ et al (2002) Aberrant splicing of FHIT transcripts in human gastric cancer cell lines. Res Commun Mol Pathol Pharmacol 112:39-49
17. Lee SH, Kim WH, Kim HK et al (2001) Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 284:850-855
18. Negrini M, Monaco C, Vorechovsky I et al (1996) The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56:3173-3179
19. Noguchi T, Muller W, Wirtz HC et al (1999) FHIT gene in gastric cancer: association with tumour progression and prognosis. J Pathol 188:378-381
20. Ohta M, Inoue H, Cotticelli MG et al (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597
21. Rocco A, Schandl L, Chen J et al (2003) Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol 129:84-88
22. Sarli L, Bottarelli L, Azzoni C et al (2004) Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer 40:1581-1588
23. Skopelitou AS, Mitselou A, Katsanos KH et al (2003) Immunohistochemical expression of Fhit protein in Helicobacter pylori related chronic gastritis, gastric precancerous lesions and gastric carcinoma: correlation with conventional clinicopathologic parameters. Eur J Gastroenterol Hepatol 15:515-523
24. Sorio C, Baron A, Orlandini S et al (1999) The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 59:1308-1314
25. Sozzi G, Veronese ML, Negrini M et al (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17-26
26. Stec-Michalska K, Antoszczyk S, Klupinska G et al (2005) Loss of FHIT expression in gastric mucosa of patients with family histories of gastric cancer and Helicobacter pylori infection. World J Gastroenterol 11:17-21
27. Tamura G, Sakata K, Nishizuka S et al (1997) Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Genes Chromosomes Cancer 20:98-102
28. Vecchione A, Sevignani C, Giarnieri E et al (2004) Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res 10:7607-7612
29. Zanesi N, Fidanza V, Fong LY et al (2001) The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98:10250-10255